<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医药投资并购俱乐部 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-13T20:29:26+08:00</updated>
  <subtitle>healthib俱乐部是医药医疗健康领域企业家与投资人的资源共享与价值共创的非营利性公众学习平台，专注于投资并购与产业整合资源的分享和学习，感谢您的关注！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>青光眼新药！唯一前房内生物可降解缓释植入物DURYSTA™（比马前列素植入物）获得了FDA批准</title>
    <updated>2020-11-13T15:42:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-13:/s/x4C_zIxmklJA3U8jKPUE2Q</id>
    <link href="https://mp.weixin.qq.com/s/x4C_zIxmklJA3U8jKPUE2Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>腔内比马前列素缓释植入物和局部比马前列素的剂量反应</title>
    <updated>2020-11-12T18:45:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/q4XNXZrIPZvysoGgVna_AQ</id>
    <link href="https://mp.weixin.qq.com/s/q4XNXZrIPZvysoGgVna_AQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>前房内缓释比马前列素植入物可将比马前列素递送至靶标组织，减少药物对靶标组织的暴露</title>
    <updated>2020-11-11T14:35:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/Di1Y57lxrJOoui0gNbavZQ</id>
    <link href="https://mp.weixin.qq.com/s/Di1Y57lxrJOoui0gNbavZQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>不同浓度比马前列素治疗青光眼或高眼压症， 时长一年的随机对照试验</title>
    <updated>2020-11-10T15:23:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/WOvSSi5qvIcAXa9TvoyvUg</id>
    <link href="https://mp.weixin.qq.com/s/WOvSSi5qvIcAXa9TvoyvUg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>比马前列素的药理作用及临床应用</title>
    <updated>2020-11-09T14:13:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/k1tlDsiMvxNDURzPRteU-Q</id>
    <link href="https://mp.weixin.qq.com/s/k1tlDsiMvxNDURzPRteU-Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>曲伏前列素——打破垄断的进程</title>
    <updated>2020-10-26T16:03:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-26:/s/7xAaW_CGunoDU6sQqTJtHQ</id>
    <link href="https://mp.weixin.qq.com/s/7xAaW_CGunoDU6sQqTJtHQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Gilteritinib-复发性/难治性FLT3突变的急性髓系白血病新标准疗法</title>
    <updated>2020-10-23T16:00:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-23:/s/s4dp8hni4k5nrV5gLqAG4g</id>
    <link href="https://mp.weixin.qq.com/s/s4dp8hni4k5nrV5gLqAG4g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Midostaurin-首个获批的FLT3抑制剂用于治疗急性髓系白血病</title>
    <updated>2020-10-22T14:57:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-22:/s/1exIrBQk0DgmOnJK8PYo9g</id>
    <link href="https://mp.weixin.qq.com/s/1exIrBQk0DgmOnJK8PYo9g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>急性髓系白血病中的FLT-3突变</title>
    <updated>2020-10-21T15:56:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-21:/s/4Oi0Tj7fxLCRme6R3HnUEg</id>
    <link href="https://mp.weixin.qq.com/s/4Oi0Tj7fxLCRme6R3HnUEg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>含聚季铵盐-1防腐剂的0.004％曲伏前列素滴眼液于青光眼的小儿患者的药代动力学和安全性研究</title>
    <updated>2020-10-20T15:14:44+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-20:/s/5sa9gU6ZO0vHNH9bwlj5Kw</id>
    <link href="https://mp.weixin.qq.com/s/5sa9gU6ZO0vHNH9bwlj5Kw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>